IN8BIO, INC.
INAB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INAB
IN8BIO, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based therapies for cancer, with a lead program in a Phase 1/2 trial and a preclinical pipeline currently suspended due to financial constraints.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 1 clinical trial for IN8BIO, INC..
IN8BIO, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based therapies for cancer, with a lead program in a Phase 1/2 trial and a preclinical pipeline currently suspended due to financial constraints.
- IN8BIO's lead product candidate, INB-100, is a non-signaling gamma-delta T cell-based chimeric antigen receptor (nsCAR) construct in a Phase 1/2 clinical trial for hematologic malignancies [sec_mda · as of 2026-08-06].
- The company has a portfolio of preclinical programs (INB-300, INB-500) that remain suspended in development due to current market interest and prioritization [sec_mda · as of 2026-08-06].
- As of June 30, 2026, IN8BIO reported cash and equivalents of $18.1 million, a net loss of $4.8 million, and shareholders' equity of $14.5 million [sec].
- The company has incurred losses since inception in 2016, has no approved products, and has not generated any revenue [sec_mda · as of 2026-08-06].
- IN8BIO has raised an aggregate of $163.2 million in gross proceeds from equity and equity-linked securities through March 31, 2026 [sec_mda · as of 2026-05-07].
What works
- IN8BIO's lead program, INB-100, is a wholly-owned, novel nsCAR construct targeting both solid and liquid tumors, currently in a Phase 1/2 trial, representing a potential first-in-class approach [sec_mda · as of 2026-08-06].
- The company has a strong intellectual property portfolio and has successfully raised $163.2 million in gross proceeds from equity and equity-linked securities through March 31, 2026 [sec_mda · as of 2026-05-07].
What to weigh
- IN8BIO has a going concern qualification, with cash of $18.1 million as of June 30, 2026, which is not expected to fund operations for at least 12 months from the date of issuance of its financial statements [sec_mda · as of 2026-08-06].
- The company has no approved products, has not generated any revenue, and has incurred net losses since inception in 2016 [sec_mda · as of 2026-08-06].
- Preclinical programs (INB-300, INB-500) are suspended, and the company is implementing cash preservation measures that may impact its ability to achieve milestones [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
The company has substantial doubt about its ability to continue as a going concern.
“there is substantial doubt about our ability to continue to operate as a going concern”
SEC MD&A · August 6, 2026
IN8BIO has raised $163.2 million in gross proceeds from securities sales through March 31, 2026.
“Through March 31, 2026, we have raised an aggregate of $163.2 million of gross proceeds from the sale of our securities”
SEC MD&A · May 7, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Cash of $18.1M as of June 30, 2026 is insufficient to fund operations for 12 months, raising substantial doubt about viability [sec_mda · as of 2026-08-06].
- No revenue or approved products — IN8BIO has no approved products and has not generated any revenue since inception in 2016 [sec_mda · as of 2026-08-06].
- Preclinical pipeline suspended — Preclinical programs INB-300 and INB-500 are suspended, limiting near-term pipeline progress [sec_mda · as of 2026-08-06].
- Cash preservation measures — Cash preservation measures may impact the timing of achieving milestones and regulatory filings [sec_mda · as of 2026-08-06].
What to watch
- Ability to raise additional capital through equity or debt offerings, including its ATM program, to fund operations beyond April 2027 [sec_mda · as of 2026-05-07].
- Progress of the Phase 1/2 clinical trial for INB-100 and any data readouts [sec_mda · as of 2026-08-06].
- Potential resumption of preclinical programs (INB-300, INB-500) if funding and market conditions improve [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run IN8BIO, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IN8BIO, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
14.6 months
D/E 0.18 · 0% dilution
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$4.6M
| Holder | Shares | Value |
|---|---|---|
| alyeska investment group, l.p. | 944,319 | $1.4M |
| franklin resources inc | 914,531 | $1.4M |
| 683 capital management, llc | 724,637 | $1.1M |
| bios capital management, lp | 167,805 | $248K |
| vanguard capital management llc | 88,865 | $132K |
| geode capital management, llc | 86,239 | $128K |
| vanguard fiduciary trust co | 43,570 | $65K |
| captrust financial advisors | 33,295 | $49K |
| oppenheimer & co inc | 24,033 | $36K |
| texas capital bank wealth management services inc | 23,750 | $35K |
Showing top 10 of 18 institutional holders of IN8BIO, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 3.4%
- Days to cover
- 3.9
- Shares short
- 296,110
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INAB short interestGovernance
Frequently asked questions
What is the AI investment thesis for IN8BIO, INC.?
IN8BIO, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based therapies for cancer, with a lead program in a Phase 1/2 trial and a preclinical pipeline currently suspended due to financial constraints.
What is IN8BIO, INC.'s lead drug candidate?
IN8BIO, INC.'s most advanced tracked candidate is inb-100 (Phase 1) for High-risk leukemias.
Who is the CEO of IN8BIO, INC.?
Mr. Tai-Wei Ho is the chief executive officer of IN8BIO, INC. (INAB).
Where is IN8BIO, INC. headquartered?
IN8BIO, INC. (INAB) is headquartered in New York, NY, United States.
What therapeutic areas does IN8BIO, INC. focus on?
IN8BIO, INC. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.